// App-Quantinova.ai

EP445 : HEMATOLOGIC ADVERSE EVENTS AND MANAGEMENT STRATEGIES FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN FIRST REMISSION RECEIVING ORAL AZACITIDINE (ORAL-AZA) IN THE PHASE 3 QUAZAR AML-001 TRIAL

Researchers

Presenter

  • Farhad Ravandi

Principal Investigators

  • Andrew Wei

  • Hartmut Dhner

  • Christopher Pocock

  • Dominik Selleslag

  • Pau Montesinos

  • Hamid Sayar

  • Maurizio Musso

  • Angela Figuera-Alvarez

  • Hana Safah

  • William Tse

  • Sang Kyun Sohn

  • Devendra Hiwase

  • Timothy Chevassut

  • Francesca Pierdomenico

  • Ignazia La Torre

  • Barry Skikne

  • Rochelle Bailey

  • Jianhua Zhong

  • CL Beach

  • ?Herv Dombret?

Medical Centers

  • The Alfred Hospital, Melbourne, Australia

  • Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, United States,

  • Hopital Saint-Louis, Assistance Publique - Hopitaux De Paris (AP-HP), Paris, FRA

  • Universitatsklinikum Ulm, Ulm, Germany

  • Kent & Canterbury Hospital, Kent, United Kingdom

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • Newyork Presbyterian Hospital, Newyork, New York, United States

  • Kent &amp

  • La Maddalena - Casa di Cura, Palermo, Italy

  • Royal Adelaide Hospital, Adelaide, Australia

  • Kyungpook National University Chilgok Hospital, Deqgu, Korea, Republic of

  • Institut de Recherche Saint-Louis, Université de Paris,Paris,France

  • Bristol Meyers Squibb,Princeton,United States

  • Pediatrics, Weill Cornell Medical College, New York, New York, United States

  • Portuguese Institute of Oncology, Lisbon, Portugal

  • Pediatric Oncology, Hospital Universitari i Politecnic La Fe, Valencia, Spain

  • Deakin University, Melbourne, Australia

  • Hospital Universitario La Paz, Madrid, Spain

  • Tulane University Health Sciences Center, New Orleans, LA, United States

  • Brighton and Sussex Medical School, Brighton, United Kingdom

  • Celgene International Sàrl, a Bristol Myers Squibb Company, Boudry, Switzerland

  • University of Kansas Medical Center, Kansas City, Kansas, United States

  • AZ Sint-Jan Brugge-Oostende, Brugge, Belgium

  • Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

Locations

  • Australia

  • United States

  • France

  • Germany

  • United Kingdom

  • Italy

  • Republic of South Korea

  • Portugal

  • Spain

  • Switzerland

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Vidaza

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved